Dr Reddy's launches Docetaxel injection in US
The company has launched the generic version of the Taxotere in the US market.
Hyderabad, November 25, 2014: Dr Reddy's Laboratories has launched the Docetaxel injection USP 20 mg/mL and 80 mg/4 mL, the generic version of the Taxotere in the US market.
The company said in a statement that its Abbreviated New Drug Application (ANDA) has been approved by the United States Food & Drug Administration (USFDA). It may be noted here that the Taxotere (docetaxel) is a cancer medication that interferes with the growth and spread of cancer cells in the body.
Its brand and generic versions have a collective sale of almost US$ 218 million MAT during the 12 month period ending September 2014.
The company also said in a statement that the Docetaxel injection USP 20 mg/mL and 80 mg/4 mL are available as a single dose, one vial formulation that does not require a prior dilution with a diluent and is ready to add to the intravenous infusion solution.